Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Change in Accured Expenses (2016 - 2025)

Protalix BioTherapeutics has reported Change in Accured Expenses over the past 16 years, most recently at $4.3 million for Q4 2025.

  • Quarterly results put Change in Accured Expenses at $4.3 million for Q4 2025, up 216.62% from a year ago — trailing twelve months through Dec 2025 was $292000.0 (down 58.05% YoY), and the annual figure for FY2025 was $292000.0, down 58.05%.
  • Change in Accured Expenses for Q4 2025 was $4.3 million at Protalix BioTherapeutics, up from -$2.1 million in the prior quarter.
  • Over the last five years, Change in Accured Expenses for PLX hit a ceiling of $4.3 million in Q4 2025 and a floor of -$3.9 million in Q2 2022.
  • Median Change in Accured Expenses over the past 5 years was $265000.0 (2023), compared with a mean of $193200.0.
  • Biggest five-year swings in Change in Accured Expenses: skyrocketed 503.01% in 2023 and later plummeted 590.96% in 2024.
  • Protalix BioTherapeutics' Change in Accured Expenses stood at $1.3 million in 2021, then plummeted by 127.83% to -$366000.0 in 2022, then skyrocketed by 503.01% to $1.5 million in 2023, then dropped by 7.39% to $1.4 million in 2024, then soared by 216.62% to $4.3 million in 2025.
  • The last three reported values for Change in Accured Expenses were $4.3 million (Q4 2025), -$2.1 million (Q3 2025), and -$610000.0 (Q2 2025) per Business Quant data.